Yazar "Daemi, Amin" seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • [ X ]
    Öğe
    Artificial intelligence-driven epigenetic CRISPR therapeutics: a structured multi-domain meta-analysis of therapeutic efficacy, off-target prediction, and gRNA optimization
    (Springer Heidelberg, 2025) Basarali, Mustafa Kemal; Daemi, Amin; Tahiraga, Ruhiyya Guliyeva; Ozbolat, Guluzar; Hooshiar, Mohammad Hosseini; Shirazi, Malihe Sagheb Ray; Dogus, Yusuf
    CRISPR-based epigenetic editing enables reversible regulation of gene expression without permanent DNA modification. The integration of artificial intelligence (AI) enhances guide RNA (gRNA) design, off-target prediction, and delivery optimization. We conducted a systematic review and meta-analysis (2015-2025) in accordance with PRISMA 2020 guidelines to evaluate the impact of AI on the precision, safety, and therapeutic efficacy of epigenetic CRISPR tools. From 540 screened records, 58 studies met inclusion criteria, of which 41 provided extractable quantitative data for meta-analysis and 17 contributed to qualitative synthesis. Random-effects models, subgroup analyses, and bias assessments were applied. Pooled analyses demonstrated strong positive effects across three domains: therapeutic efficacy (SMD = 1.67), gRNA optimization (SMD = 1.44), and off-target prediction (AUC = 0.79). Publication bias was minimal, and subgroup analyses indicated the strongest impact in therapeutic applications. Deep learning models were consistently associated with higher effect sizes. Qualitative synthesis revealed trends in interpretable AI, omics integration, and delivery innovations, underscoring AI's role in safer and more precise CRISPR editing. Overall, AI significantly improves the precision and therapeutic performance of CRISPR-based epigenetic tools, with the strongest effects observed in therapeutic efficacy, supporting their potential for personalized gene editing.
  • [ X ]
    Öğe
    Effectiveness of vitamin D3 in facilitating the therapeutic progression of healing diabetic foot ulcers
    (Chulalongkorn University Printing House, 2025) Nouri, Fatemeh; Aghaei, Sara; Özbolat, Gülüzar; Döğüş, Yusuf; Mirhamidi, Mahdi; Barghani, Mahmoud Reza Rahimi; Daemi, Amin
    Background: Diabetes and its complications afflict a large portion of the population worldwide, and it is estimated that its prevalence in all age groups will increase from 2.8% in 2000 to 4.4% in 2030. Moreover, it is well known that vitamin D may cause rapid wound healing and exert anti-inflammatory effects. Objective: This study aimed to investigate the efficacy of vitamin D3 on the healing of chronic diabetic foot ulcers to improve the quality of life of patients with diabetes. The present research is conducted as a randomized controlled trial. Methods: Forty patients were randomly divided into an experimental group (vitamin D supplementation) and a control group (placebo) using a sampling method based on the inclusion criteria. The patients were evaluated for ulcer debridement every two weeks (0 (T0), 2 (T1), 4 (T2), 6 (T3), 8 (T4), 10 (T5), and 12 (T6)) after the intervention. The collected data were analyzed using SPSS-23 software. Results: The experimental group exhibited significantly decreased ulcer length (−1.6 ± 0.8 cm vs. −0.5 ± 1.4 cm, P = 0.005), ulcer width (−1.7 ± 1.2 cm vs. −0.9 ± 1.2 cm, P = 0.025), and ulcer depth (−0.6 ± 0.5 cmvs. −0.3 ± 0.4 cm, P = 0.025) after 12 weeks of intervention compared to those of the control group. These results reveal that vitamin D had a significant relationship with all stages of the wound-healing process (P < 0.01). Conclusions: In patients with chronic diabetic foot ulcers, the use of vitamin D supplementation can improve wound healing. Moreover, vitamin D had a significant relationship with all stages of the wound-healing process except re-epithelialization and angiogenesis. © 2025, Chulalongkorn University Printing House. All rights reserved.
  • [ X ]
    Öğe
    Investigating monoclonal antibody against cytokeratin 19 tumor marker
    (Bmc, 2025) Momeni-Moghaddam, Mohammad Amin; Mohammadnejad, Javad; Ghahremani, Hossein; Khaghani, Shahnaz; Moradi, Nariman; Daemi, Amin; Ozbolat, Guluzar
    Cytokeratin 19 (CK 19) is a member of the intermediate filaments that are widely expressed in thyroid, breast, colon, small and non-small cell lung, and prostate cancer cells. This paper aims to produce the monoclonal antibody against CK 19. Recombinant CK 19 was used to immunize of two 6-8 weeks old female Balb/c mice. For the first injection, recombinant antigen was mixed with the complete Freund ' s Adjuvant, and for the second and third injections, mixed with the Incomplete Freund ' s Adjuvant. Injections were performed at intervals of 15 days. Four days after the third injection, titration of mice serum was determined using indirect ELISA and better-immunized mice selected for fusion. Intravenous (IV) injection was performed 4 days before the fusion. The spleen cells of the mice were fused with sp2/0 cells using 50% v/v polyethylene glycol (PEG) and cells were suspended in HAT (Hypoxanthine-Aminopterin-Thymidine) medium. Supernatants of hybridoma cells were screened for antibody secretion by indirect ELISA. Two stable hybridomas were obtained among 78 hybridoma clones that reacted with the recombinant CK 19 by indirect ELISA. These hybridoma cells were monoclonal twice by limiting dilution. Besides, immunization by recombinant CK 19 led to the obtaining of two stable monoclonal antibodies against this antigen. Western blotting with HT-29 cell line demonstrated a band of upper than 43 kDa. Result of HepG2 indicated a band of lower than 45 kDa while MCF7 bands of 45 kDa and higher were observed for MCF7. A431 cell line was epidermoid carcinoma, as CK 19 did not exist in the epidermis, therefore no band was observed in A431 cell line.
  • [ X ]
    Öğe
    Investigating the Effects of Curcumin on Lipid Metabolism and Cell Viability in HepG2 Cells: Potential Therapeutic Implications for Nonalcoholic Fatty Liver Disease
    (Wiley, 2025) Qaleban, Faeze; Mohammadnejad, Javad; Daemi, Amin; Ozbolat, Guluzar; Dogus, Yusuf
    Metabolic dysfunction-associated steatotic liver disease (MASLD), poses a significant global health challenge, necessitating novel therapeutic strategies. This study investigates examines the efficacy of curcumin (Cur), a natural bioactive compound, in suppressing inhibiting the proliferation of hepatocellular carcinoma proliferation and reducing lipid accumulation in vitro. HepG2 cells were treated with Cur (1.25-10 mu g/mL) for 24-72 h, revealing a dose- and time-dependent reduction in viability, with an IC50 of 10 mu g/mL at 72 h. Oil Red O staining demonstrated Cur's lipid-lowering effects, reducing lipid content by 57% at 5 mu g/mL and 78% at 10 mu g/mL, suggesting enhanced efficacy at higher concentrations. Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) analysis revealed that Cur downregulated key lipogenic regulators Peroxisome proliferator-activated receptor gamma (PPAR gamma) and CCAAT/enhancer-binding protein alpha (C/EBP-alpha) by 2.3- and 1.8-fold, respectively, while modulating 14-3-3 gamma/beta expression, implicating these pathways in its mechanism. These findings highlight Cur's potential to attenuate hepatic lipid accumulation and cancer cell growth in vitro, warranting further validation in primary hepatocytes and preclinical models to advance its therapeutic prospects for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
  • [ X ]
    Öğe
    Revolutionizing personalized medicine using artificial intelligence: a meta-analysis of predictive diagnostics and their impacts on drug development
    (Springer-Verlag Italia Srl, 2025) Daemi, Amin; Kalami, Sahar; Tahiraga, Ruhiyya Guliyeva; Ghanbarpour, Omid; Barghani, Mohammad Reza Rahimi; Hooshiar, Mohammad Hosseini; Ozbolat, Guluzar
    Artificial intelligence (AI) is transforming the landscape of laboratory medicine by enhancing diagnostic accuracy and enabling more personalized care. Given its growing use in clinical settings, evaluating the performance of AI models in diagnostic tasks is essential to inform evidence-based implementation strategies. This meta-analysis systematically assessed the diagnostic effectiveness of AI-based models. A comprehensive literature search was conducted in PubMed, Scopus, Web of Science, and IEEE Xplore using predefined keywords related to AI and diagnostic accuracy. From 430 retrieved studies, 17 met the inclusion criteria. Data extracted included study design, AI model type, input modality, and performance metrics such as sensitivity, specificity, and area under the curve (AUC). Random-effects meta-analysis and subgroup analyses were performed to investigate heterogeneity and model-specific trends. The pooled analysis yielded a high combined AUC of 0.9025, indicating strong diagnostic capability of AI models. However, substantial heterogeneity was detected (I2 = 91.01%), attributed to differences in model architecture, diagnostic domains, and data quality. Subgroup analyses showed that convolutional neural networks and random forest models achieved higher AUC values, while domains like endocrinology demonstrated greater performance variability. Funnel plot inspection and sensitivity analysis indicated the presence of publication bias. AI shows strong potential to enhance diagnostic accuracy in personalized laboratory medicine. Nonetheless, methodological heterogeneity and publication bias remain significant challenges. Future research should prioritize standardized evaluation frameworks, transparency, and the development of explainable AI systems to ensure responsible clinical integration.
  • [ X ]
    Öğe
    Sodium butyrate entrapped chitosan-PAMAM for suppression of colorectal cancer cells
    (Bmc, 2025) Al-Zihaymee, Ruaa Mahdi Mayih; Mohammadnejad, Javad; Narmani, Asghar; Jafar, Hanieh; Ozbolat, Guluzar; Daemi, Amin; Dogus, Yusuf
    Objective Cancer treatment is a major concern of health worldwide. Nowadays, colorectal cancer is one of the most prevalent diseases throughout the globe. Therefore, novel cancer treatment modalities are required to stop cancer. Thus, this paper aims to develop a novel drug delivery system (DDS) based on Chitosan (CS), polyamidoamine (PAMAM G4), and Nanoparticles (NP) for efficient delivery of sodium butyrate (NB) and Fe2O3 to SW480 colorectal cancer cells. Methods To do so, after characterizing the nanocarrier with FT-IR, DLS, TEM, and TGA, nanometric size (40-65 nm), high drug content (23% Fe2O3 and 3% NB), controlled NB release (4% within 2 h), and pH-sensitive NB release (35% within 2 h) were measured for CS-PAMAM-Fe2O3-NB. Result In biomedical tests, MTT assay indicated 10% (after 24 h), 8% (after 48 h), and 7% (after 72 h) cell viabilities for 200 nM concentration of CS-PAMAM-Fe2O3-NB nanocarrier on SW480 cells while pure NB did not have potential toxicity on cancer cells. IC50 determined for 25 nM after 24 h. qRT-PCR test indicated a 7-fold and 10-fold increase for Caspase9 and Bax apoptotic genes whereas 0.3-fold expression quantified for Bcl2 anti-apoptotic gene. Conclusion According to the obtained results, it can be concluded that the fabricated nanocarrier would be a potential DDS against colorectal cancer cells. The results of these biomedical tests have approved potential the ability of the synthesized DDS in the inhibition of colorectal cancer cells. High biocompatibility was shown in MSC normal cells which further verified the efficiency of CS-PAMAM-Fe2O3-NB.